Clinical Trial Update: Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC [Phase 3]

View source ↗

Summary

Phase 3 trial comparing JMKX001899 to docetaxel in previously treated KRAS G12C-mutant non-small cell lung cancer is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• JMKX001899

Snippet

Sponsor: Jemincare | Conditions: NSCLC (Non-small Cell Lung Cancer) | Phase 3 | Status: NOT_YET_RECRUITING